TY  - GEN 
AU  - Armario Hita, José Carlos
AU  - Pereyra Rodríguez, J. J.
AU  - González-Quesada, A.
AU  - Herranz, P.
AU  - Suarez, R.
AU  - Galán-Gutiérrez, M.
AU  - Rodríguez-Serna, M.
AU  - Ortiz de Frutos, J.
AU  - Carrascosa, J. M.
AU  - Serra Baldrich, E.
AU  - Ara-Martin, M.
AU  - Figueras Nart, I.
AU  - Silvestre, J.F.
AU  - Ruiz-Villaverde, R.
A4  - Medicina
PY  - 2024
SN  - 1365-4632
SN  - 0011-9059
UR  - http://hdl.handle.net/10498/33679
AB  - Background: Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited. Objectives: This study aimed...
LA  - eng
PB  - John Wiley and Sons Inc
KW  - abrocitinib
KW  - atopic dermatitis
KW  - JAK inhibitors
KW  - Spain
KW  - treatment
TI  - Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
DO  - 10.1111/ijd.17344
ER  -